Why Compounding Matters (and When It Does Not)

Most patients who receive compounded peptides have only a vague sense of what compounding is, who is doing it, and how it differs from the manufacturing process behind FDA-approved pharmaceuticals. This is not a trivial gap. The compounding pharmacy that fills your prescription has substantial influence over what you actually receive — its identity, potency, sterility, and consistency. Understanding the compounding regulatory landscape helps you evaluate whether your care meets reasonable quality standards.

This article explains what compounding is, the difference between 503A and 503B pharmacies, when compounding matters most, and what to ask your prescriber about the pharmacy filling your prescription.

What compounding actually is

Compounding is the process of preparing a medication for an individual patient based on a physician’s prescription. The compounding pharmacy combines pharmaceutical ingredients (active ingredients and excipients) according to a specific formula to produce a finished medication ready for the patient.

This is fundamentally different from manufacturing. A pharmaceutical manufacturer produces large batches of finished products that are tested, packaged, and distributed broadly. A compounding pharmacy prepares individual or small-batch medications based on prescriptions for specific patients.

Compounding has a very long history in medicine. Before the rise of modern pharmaceutical manufacturing in the early 20th century, virtually all medications were compounded in pharmacies. Even today, compounding fills important clinical roles: preparing pediatric formulations of adult medications, creating dye-free or preservative-free versions for patients with sensitivities, providing medications during commercial shortages, and dispensing peptides and other agents that are not commercially manufactured but are clinically appropriate.

The two regulatory categories: 503A and 503B

The Drug Quality and Security Act of 2013 established two regulatory frameworks for compounding pharmacies, named after sections of the Federal Food, Drug, and Cosmetic Act that they amended.

503A traditional compounding pharmacies prepare medications for individual patients on a prescription-by-prescription basis. They are regulated primarily by state pharmacy boards rather than the FDA. They cannot legally produce medications in advance of receiving prescriptions, and they cannot ship medications across state lines in large quantities. Their compounding standards are governed by USP (United States Pharmacopeia) chapters, particularly USP <795> for non-sterile compounding and USP <797> for sterile compounding.

503A pharmacies vary widely in size, sophistication, and quality. Some are small neighborhood pharmacies that compound a handful of prescriptions per week. Others are large specialty operations that compound thousands of complex prescriptions annually with sophisticated quality control. The regulatory minimum standards apply to all of them, but practice quality varies substantially.

503B outsourcing facilities are a newer category created specifically to address gaps that became visible after the 2012 New England Compounding Center fungal meningitis outbreak. 503B facilities can produce sterile compounded medications in bulk without individual prescriptions, can ship to healthcare facilities, and operate under more rigorous quality standards than 503A pharmacies. They register with the FDA, follow current Good Manufacturing Practice (cGMP) standards similar to pharmaceutical manufacturers, and undergo FDA inspections.

503B compliance is substantially more demanding than 503A compliance. The facility design, environmental monitoring, equipment qualification, batch documentation, stability testing, and quality assurance systems are all held to higher standards. The trade-off is that 503B operations are larger, more expensive to operate, and produce a narrower range of products than the 503A market.

Why this matters for peptides specifically

Most compounded peptides are sterile injectable products. Sterile compounding is significantly more demanding than non-sterile compounding because contamination directly enters the bloodstream when the patient injects the medication. The 2012 fungal meningitis outbreak, which killed 64 people and sickened over 700, was caused by sterile injectable products from a 503A pharmacy that did not maintain adequate sterility controls.

For sterile injectable peptides, the quality standards of the compounding pharmacy translate directly into patient safety. The pharmacy environment must maintain controlled air quality. Equipment must be regularly qualified and validated. Personnel must undergo specific training and aseptic technique testing. Each batch must be subjected to sterility testing, endotoxin testing, and potency verification.

Pharmacies that perform these steps rigorously produce peptide products that consistently meet specifications. Pharmacies that cut corners produce variable products with unpredictable risks. The patient typically cannot tell the difference from looking at the vial — both will look like clear liquid or reconstituted powder.

The compounding gray zone for high-volume peptides

Several peptides have been the subject of recent regulatory attention because of the intersection between FDA-approved versions and compounded versions.

When a peptide is FDA-approved as a commercial product (for example, semaglutide as Ozempic, Wegovy, and Rybelsus), the general rule is that compounding essentially identical copies is restricted. Compounding pharmacies generally cannot produce copies of commercially available FDA-approved drugs. Exceptions exist for documented drug shortages, for patient-specific clinical needs that the commercial product cannot meet, and for certain other narrow circumstances.

The semaglutide and tirzepatide situation illustrates this. When these drugs were on the FDA Drug Shortage List, compounding pharmacies could legally compound versions to address the shortage. When the FDA officially declared the shortages resolved, the regulatory pathway for general semaglutide and tirzepatide compounding closed substantially. Some compounding remains legal under specific narrow circumstances, but broad compounding of these specific drugs has been the subject of FDA enforcement action.

This regulatory landscape is important context for patients. A clinic offering “compounded semaglutide” or “compounded tirzepatide” should be able to explain the specific legal basis for the compounding (drug shortage, individualized formulation requirement, or other documented basis). A clinic that cannot articulate this basis is operating in a gray zone that may close suddenly under enforcement action.

When compounding matters most

Compounding quality matters most for sterile injectable products, particularly those administered repeatedly over long courses of therapy. The cumulative exposure to subtle quality issues can produce subtle problems that may not be immediately visible.

Compounding quality matters less for short-course oral products and topical products, where the contamination and sterility risks are lower and the consequences of variability are more limited.

For peptide therapy specifically, virtually everything that we prescribe injectable falls into the category where compounding quality matters substantially. This is why the choice of compounding pharmacy is a meaningful clinical decision rather than an administrative detail.

What to ask about your compounding pharmacy

If your peptide prescription is being filled by a compounding pharmacy, useful questions include:

What is the pharmacy’s regulatory category? 503A or 503B. Both can produce quality products; 503B operations meet higher minimum standards.

Does the pharmacy follow USP chapters for sterile compounding? The answer should be specifically “yes, USP <797>” for sterile injectable products.

What state board licenses the pharmacy? You can verify license status with the state pharmacy board.

Does the pharmacy publish results of third-party testing? Reputable operations test for sterility, endotoxin, and potency on each batch and can provide certificates of analysis.

How does the pharmacy handle adverse event reporting? Quality operations have systems to track and address reported issues.

You should not need to ask all of these questions of every prescription, but knowing where your peptides come from is reasonable due diligence — particularly if you are starting long-term therapy.

How The Tide handles compounding

We work with a small number of selected compounding pharmacies that meet specific quality standards. We prefer 503B outsourcing facilities for sterile injectable products when available, because the higher regulatory standards translate to more consistent product quality. We use specific 503A pharmacies for products and patient-specific formulations not available through 503B sources.

Our pharmacy partners are willing to provide certificates of analysis for batches we receive, follow USP standards for the compounding categories they handle, and have established adverse event reporting systems. We discontinue relationships with pharmacies that do not maintain these standards.

This is not a unique standard — many quality peptide-focused practices operate this way. But it is also not universal. Patients who arrive at The Tide having previously received compounded peptides from sources their previous clinic could not name, or that did not meet basic quality standards, are unfortunately not rare.

Bottom line

Compounding is a legitimate and important part of medical practice, including peptide therapy. The quality of the compounding pharmacy substantially affects what you actually receive in your prescription. The regulatory categories (503A and 503B) and the USP standards within them provide a framework for evaluating quality. The right questions to your prescriber and pharmacy are reasonable due diligence and should be welcomed by competent practices.

Compounding does not need to be intimidating, but it does deserve the same attention you would give to any aspect of your medical care. Knowing where your medications come from and how they are made is part of being an informed patient.